AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9817340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 30 microg
Number of subjects: 5
Study 9817340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 45 microg
Number of subjects: 5
Study 9817340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 7847127 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cisternography (CAc)
Number of subjects: 8
Study 7847127 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 8
Study 7847127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CAc and MRI
Number of subjects: 8
Study 2679864 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of elemental calcium per day
Number of subjects: 106
Study 2679864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 367057 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 22
Study 367057 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 15 mg
Number of subjects: 22
Study 367057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31507088 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir gel provided through family planning clinics (intervention clinics), n = 189
Number of subjects: 372
Study 31507088 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir gel provided through CAPRISA research clinics (control clinics), n = 183
Number of subjects: 372
Study 31507088 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir gel provided through family planning clinics (intervention clinics)
Number of subjects: 372
Study 31507088 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir gel provided through CAPRISA research clinics (control clinics)
Number of subjects: 372
Study 28963158 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine-alcohol followed by chlorhexidine gluconate-alcohol (PVI + CHG)
Number of subjects: 407
Study 28963158 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine-alcohol applied twice (PVI)
Number of subjects: 407
Study 26193204 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D ultrasound evaluation of fetal cerebral structures (choroid plexus, thalamus, cerebellum, hippocampus, Sylvian fissure)
Number of subjects: 232
Study 26193204 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological and immunohistochemical assessment
Number of subjects: 232
Study 22867815 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharged group
Number of subjects: 42
Study 22867815 — intervention group
Group type: COMPARATOR
Intervention: Admitted group
Number of subjects: 42
Study 20624673 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomalto-oligosaccharides (IO) 10 g/d for 8 weeks
Number of subjects: 13
Study 19175374 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI diet
Number of subjects: 104
Study 19175374 — intervention group
Group type: COMPARATOR
Intervention: CCE diet
Number of subjects: 104
Study 16478762 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel applied locally to the cervix 1 min before cervical manipulation/dilatation
Number of subjects: 131
Study 16478762 — intervention group
Group type: COMPARATOR
Intervention: Placebo (KY Jelly) applied locally to the cervix 1 min before cervical manipulation/dilatation
Number of subjects: 131
Study 16478762 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel
Number of subjects: 131
Study 16939913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (30 mg/m(2))
Number of subjects: 36
Study 16939913 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation
Number of subjects: 36
Study 16939913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin administration
Number of subjects: 36
Study 14992337 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microM RTX
Number of subjects: 36
Study 14992337 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microM RTX
Number of subjects: 36
Study 14992337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10484427 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired O2 fraction of 0.21
Number of subjects: 11
Study 10484427 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired O2 fraction of 0.30
Number of subjects: 11
Study 8954288 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% MVC
Number of subjects: 10
Study 8954288 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% MVC
Number of subjects: 10
Study 8954288 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% MVC
Number of subjects: 10
Study 8954288 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% MVC
Number of subjects: 10
Study 8954288 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% MVC
Number of subjects: 10
Study 2026743 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional, high carbohydrate Pima Indian diet
Number of subjects: 12
Study 2026743 — intervention group
Group type: COMPARATOR
Intervention: Modern, high fat western diet
Number of subjects: 12
Study 2026743 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 12
Study 6795043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich diet (54 energy-% fat, 29 energy-% carbohydrate)
Number of subjects: 23
Study 6795043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-poor diet (29 energy-% fat, 53 energy-% carbohydrate)
Number of subjects: 23
Study 6795043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary diet
Number of subjects: 23
Study 6795043 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary changes)
Number of subjects: 23
Study 31654485 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disposable hydrogel contact lenses (etafilcon A)
Number of subjects: 581
Study 31654485 — intervention group
Group type: COMPARATOR
Intervention: Spectacle wearers
Number of subjects: 581
Study 31642245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose bortezomib (1.0-1.3 mg/m2) on day 1, day 4, day 8, and day 11, with 21 days as a chemotherapy cycle.
Number of subjects: 86
Study 31642245 — intervention group
Group type: COMPARATOR
Intervention: High dose bortezomib (1.6 mg/m2) on day 1, day 8, day 15, and day 22, with 35 days as a chemotherapy cycle.
Number of subjects: 86
Study 28065379 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-gauge side-holes catheter
Number of subjects: 180
Study 28065379 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge end-hole catheter
Number of subjects: 180
Study 25847610 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 62
Study 25847610 — intervention group
Group type: COMPARATOR
Intervention: Canaloplasty
Number of subjects: 62
Study 23778373 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with postoperative physiotherapy (anterior cervical decompression and fusion plus physiotherapy program)
Number of subjects: 63
Study 23778373 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 63
Study 21125288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 154
Study 21125288 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 154
Study 19167662 — intervention group
Group type: EXPERIMENTAL
Intervention: education intervention
Number of subjects: 391
Study 19167662 — intervention group
Group type: EXPERIMENTAL
Intervention: education intervention with booster
Number of subjects: 391
Study 19167662 — intervention group
Group type: COMPARATOR
Intervention: no systematic intervention
Number of subjects: 391
Study 17380809 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride and sodium hexametaphosphate dentifrice (Crest Pro‐Health)
Number of subjects: 59
Study 17380809 — intervention group
Group type: COMPARATOR
Intervention: Colgate Total + Whitening (positive control)
Number of subjects: 59
Study 15119752 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine 10 mg plus pseudoephedrine 120 mg
Number of subjects: 62
Study 15119752 — intervention group
Group type: COMPARATOR
Intervention: Loratadine 5 mg plus pseudoephedrine 120 mg
Number of subjects: 62
Study 11694895 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 degrees tilt for 45 min
Number of subjects: 201
Study 11694895 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 degrees tilt for 45 min
Number of subjects: 201
Study 11694895 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 degrees tilt drug-free
Number of subjects: 201
Study 11694895 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 degrees tilt drug-free
Number of subjects: 201
Study 11694895 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 60 degrees
Number of subjects: 201
Study 11694895 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 80 degrees
Number of subjects: 201
Study 9126518 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury prevention campaign on Naxos involving trained local collaborators providing weekly visits and advice.
Number of subjects: 349
Study 9126518 — intervention group
Group type: COMPARATOR
Intervention: Control group on Spetses with untrained collaborators visiting households.
Number of subjects: 349
Study 9126518 — intervention group
Group type: COMPARATOR
Intervention: Overall injury incidence among target groups on Naxos vs Spetses.
Number of subjects: 349
Study 9126518 — intervention group
Group type: COMPARATOR
Intervention: Home accidents incidence among target groups on Naxos vs Spetses.
Number of subjects: 349
Study 8368543 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 degrees reverse Trendelenburg tilt
Number of subjects: 30
Study 8368543 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position (Control)
Number of subjects: 30
Study 3122880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (up to 100 mg/kg/day)
Number of subjects: 8
Study 3122880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one with ascorbic acid
Number of subjects: 8
Study 3122880 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous desferrioxamine (at comparable dose)
Number of subjects: 8
Study 31146738 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralized health units
Number of subjects: 812
Study 31146738 — intervention group
Group type: COMPARATOR
Intervention: Main hospital
Number of subjects: 812
Study 31146738 — intervention group
Group type: EXPERIMENTAL
Intervention: Convenient location, shorter commute times, shorter wait times
Number of subjects: 812
Study 28474112 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal laser ablation (TPLA)
Number of subjects: 18
Study 25442234 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher worksite neighborhood socioeconomic status (NSES)
Number of subjects: 0
Study 25442234 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher density of residential units surrounding worksites
Number of subjects: 0
Study 25442234 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential density
Number of subjects: 0
Study 23939511 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day baclofen
Number of subjects: 180
Study 23939511 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/day baclofen
Number of subjects: 180
Study 23939511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 23939511 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day baclofen (in pharmacokinetic and cue-reactivity component)
Number of subjects: 180
Study 23939511 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/day baclofen (in pharmacokinetic and cue-reactivity component)
Number of subjects: 180
Study 21560488 — intervention group
Group type: EXPERIMENTAL
Intervention: Siriraj Mite Allergen Vaccine (SMAV) Dp at 2,500 AU/ml
Number of subjects: 54
Study 21560488 — intervention group
Group type: EXPERIMENTAL
Intervention: Siriraj Mite Allergen Vaccine (SMAV) Dp at 10,000 AU/ml
Number of subjects: 54
Study 21560488 — intervention group
Group type: EXPERIMENTAL
Intervention: Siriraj Mite Allergen Vaccine (SMAV) Df at 10,000 AU/ml
Number of subjects: 54
Study 21560488 — intervention group
Group type: COMPARATOR
Intervention: Commercial standardized mite allergen vaccine Dp at 2,500 AU/ml
Number of subjects: 54
Study 21560488 — intervention group
Group type: COMPARATOR
Intervention: Commercial standardized mite allergen vaccine Df at all concentrations
Number of subjects: 54
Study 19839877 — intervention group
Group type: EXPERIMENTAL
Intervention: RF (5 sessions, 1 every 10 days)
Number of subjects: 30
Study 19839877 — intervention group
Group type: EXPERIMENTAL
Intervention: LED (8 sessions, 1 every 5 days)
Number of subjects: 30
Study 19839877 — intervention group
Group type: EXPERIMENTAL
Intervention: RF and LED (3 RF sessions and 6 LED sessions, 1 RF and 2 LED every 5 days)
Number of subjects: 30
Study 16750996 — intervention group
Group type: EXPERIMENTAL
Intervention: 3130C carriers of the MBL2 gene
Number of subjects: 0
Study 16750996 — intervention group
Group type: EXPERIMENTAL
Intervention: 3130G carriers of the MBL2 gene
Number of subjects: 0
Study 16750996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwild-type MBL2 carriers
Number of subjects: 0
Study 16750996 — intervention group
Group type: COMPARATOR
Intervention: Wild-type MBL2 carriers
Number of subjects: 0
Study 15466644 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan, titrated to 32 mg QD
Number of subjects: 7599
Study 15466644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study 12225705 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine cigarettes
Number of subjects: 0
Study 12225705 — intervention group
Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes
Number of subjects: 0
Study 12225705 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine nasal spray
Number of subjects: 0
Study 12225705 — intervention group
Group type: COMPARATOR
Intervention: Placebo nicotine nasal spray
Number of subjects: 0
Study 12225705 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine cigarettes and Denicotinized cigarettes
Number of subjects: 0
Study 9584032 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Dates program (treatment)
Number of subjects: 1886
Study 9584032 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1886
Study 7664561 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniotomy
Number of subjects: 53
Study 7664561 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 53
Study 2752600 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack-HD (standard snack of about 400 Kcal)
Number of subjects: 13
Study 2752600 — intervention group
Group type: COMPARATOR
Intervention: Control-HD (no snack)
Number of subjects: 13
Study 31853116 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation laboratory with standardized patient
Number of subjects: 66
Study 31853116 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 66
Study 27739936 — intervention group
Group type: EXPERIMENTAL
Intervention: Social anxiety
Number of subjects: 450
Study 26303812 — intervention group
Group type: EXPERIMENTAL
Intervention: 5As Team (5AsT) intervention
Number of subjects: 29
Study 23593643 — intervention group
Group type: COMPARATOR
Intervention: G1: no treatment
Number of subjects: 50
Study 23593643 — intervention group
Group type: EXPERIMENTAL
Intervention: G2: adhesive application
Number of subjects: 50
Study 23593643 — intervention group
Group type: EXPERIMENTAL
Intervention: G3: silane + adhesive
Number of subjects: 50
Study 23593643 — intervention group
Group type: EXPERIMENTAL
Intervention: G4: sandblasting (Al2O3) + adhesive
Number of subjects: 50
Study 23593643 — intervention group
Group type: EXPERIMENTAL
Intervention: G5: sandblasting (Al2O3) + silane + adhesive
Number of subjects: 50
Study 21880994 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 585
Study 21880994 — intervention group
Group type: COMPARATOR
Intervention: Enzyme-inducing AED (EIAED)
Number of subjects: 585
Study 21880994 — intervention group
Group type: COMPARATOR
Intervention: No AED
Number of subjects: 585
Study 19393405 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid alginate suspension
Number of subjects: 40
Study 16784587 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic dental analgesia (EDA) device - Team Up Duo (active state)
Number of subjects: 81
Study 16784587 — intervention group
Group type: COMPARATOR
Intervention: Electronic dental analgesia (EDA) device - Team Up Duo (inactive state)
Number of subjects: 81
Study 16784587 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic dental analgesia (EDA) device - Team Up Duo
Number of subjects: 81
Study 15254561 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulfate exposure during preterm labor
Number of subjects: 140
Study 15254561 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 140
Study 11084272 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco-chop
Number of subjects: 40
Study 11084272 — intervention group
Group type: COMPARATOR
Intervention: Stop-and-chop
Number of subjects: 40
Study 8816209 — intervention group
Group type: EXPERIMENTAL
Intervention: Two aliquots of surfactant
Number of subjects: 20
Study 8816209 — intervention group
Group type: EXPERIMENTAL
Intervention: Six aliquots of surfactant
Number of subjects: 20
Study 8816209 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant instillation (both groups)
Number of subjects: 20
Study 1446992 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (Fz) 10 mg/d
Number of subjects: 42
Study 1446992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 4076324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimalan
Number of subjects: 12
Study 4076324 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox
Number of subjects: 12
Study 4076324 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol alone
Number of subjects: 12
Study 31524938 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding diabetes medications; 410 participants rated importance of 7 factors.
Number of subjects: 818
Study 31524938 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping diabetes medications; 408 participants rated importance of 7 factors.
Number of subjects: 818
Study 28601716 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety evaluated by Hospital Anxiety and Depression Scale-anxiety subscale at baseline.
Number of subjects: 828
Study 28601716 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety evaluation in ACS patients.
Number of subjects: 828
Study 26052565 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with BMMNC transplantation
Number of subjects: 42
Study 26052565 — intervention group
Group type: COMPARATOR
Intervention: CABG only
Number of subjects: 42
Study 23970305 — intervention group
Group type: EXPERIMENTAL
Intervention: ω3 polyunsaturated fatty acid enriched lipid emulsion
Number of subjects: 14
Study 23970305 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil
Number of subjects: 14
Study 21558567 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (TG; twice per week for 12 weeks)
Number of subjects: 19
Study 21558567 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 19
Study 21558567 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 20137540 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d) and probucol (500 mg/d) for 4 weeks (combination group)
Number of subjects: 30
Study 20137540 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (20 mg/d) for 4 weeks (atorvastatin group)
Number of subjects: 30
Study 20137540 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Atorvastatin and combination)
Number of subjects: 30
Study 16316886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored hypnotic induction
Number of subjects: 8
Study 16316886 — intervention group
Group type: COMPARATOR
Intervention: Manualized hypnotic induction (Palsson's protocol)
Number of subjects: 8
Study 15232805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway
Number of subjects: 86
Study 15232805 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 86
Study 11575866 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (0.5, 1, and 2 mg/d)
Number of subjects: 70
Study 11575866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9059469 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 16
Study 9059469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9059469 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy (for patients with best CPAP use)
Number of subjects: 16
Study 9059469 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy (compliance comparison)
Number of subjects: 16
Study 7903218 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg
Number of subjects: 17
Study 7903218 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 160 mg (SR)
Number of subjects: 17
Study 3898795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous timolol
Number of subjects: 135
Study 3898795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 3169487 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 23
Study 3169487 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 23
Study 3169487 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (indomethacin and control)
Number of subjects: 23
Study 29860473 — intervention group
Group type: EXPERIMENTAL
Intervention: Macimorelin (single-dose oral)
Number of subjects: 139
Study 29860473 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance test (ITT)
Number of subjects: 139
Study 29860473 — intervention group
Group type: EXPERIMENTAL
Intervention: Macimorelin (retesting)
Number of subjects: 139
Study 28270180 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupressure therapy (PC6, LI4, HT7 acupressure performed three times a day for 2 days)
Number of subjects: 150
Study 28270180 — intervention group
Group type: COMPARATOR
Intervention: Light touch (sham acupressure, performed three times a day for 2 days)
Number of subjects: 150